ArticleJournal of nanobiotechnology2025
Biological nanoparticles from Brucella abortus
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Quantitative proteomics identifies GntR as a novel potential DIVA antigen for bovine brucellosis.Applied microbiology and biotechnology · 2026Article
- Bacterial extracellular vesicles as multifaceted regulators of human diseases and emerging therapeutic platforms.Theranostics · 2026Review
- Outer Membrane Vesicles AttenuateMicroorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Brucellosis, caused by bacteria of the genus Brucella, is a globally prevalent zoonotic disease that poses serious risks to both animal and human health. Brucella abortus releases the biological nanoparticles (outer-membrane-vesicles, OMVs), which contribute to chronic infection by promoting host invasion and immune evasion. In this study, we performed a detailed characterization of OMVs derived from the wild-type B. abortus strain. These OMVs enhanced bacterial invasion and intracellular survival in macrophages ex vivo and increased pathogenicity in mice by modulating macrophage polarization in vivo. However, native OMVs showed low yield and limited immunogenicity. To overcome these limitations, we engineered a recombinant B. abortus strain Bru-M3, by deleting the eipB, per, and wadC genes (Brucella abortus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.